ArticleTheranostics2020
Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 84 citations in OpenAlex.
- Construction of selenium nanoparticles for the transmembrane absorption ofRSC advances · 2026Article
- Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Selenium Induces Ferroptosis in Colorectal Cancer Cells via Direct Interaction with Nrf2 and Gpx4.Biological trace element research · 2026Article
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip.Journal of advanced research · 2026Article
- Natural polysaccharides as multifunctional anti-cancer agents: structure-activity relationships, mechanisms of action, and therapeutic potential.Frontiers in immunology · 2026Review
- Selenium Nanoparticles as Versatile Delivery Tools.Pharmaceutics · 2025Review
- Recent Advances Towards Selenium Nanoparticles: Synthetic Methods, Functional Mechanisms, and Biological Applications.Foods (Basel, Switzerland) · 2025Review
- Advances in selenium-based nanomedicines for cardiovascular disease therapy: mechanisms, current trends, and prospects.Nanomedicine (London, England) · 2025Review
- Article
- GPx-mimetic selenium-enriched yeast nanozymes ameliorate diabetic bone disease via dual-targeting of ROS scavenging and angiogenesis-osteogenesis coupling.Materials today. Bio · 2025Article
- Mechanisms of action of fungal polysaccharides and their therapeutic effect.European journal of clinical nutrition · 2025Review
- Selenium nanoparticles attenuate retinal pathological angiogenesis by disrupting cell cycle distribution.Nanomedicine (London, England) · 2025Article
- Tumour cell-released autophagosomes promote lung metastasis by upregulating PD-L1 expression in pulmonary vascular endothelial cells in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Review
- Selenium nanoparticles alleviate renal ischemia/reperfusion injury by inhibiting ferritinophagy via the XBP1/NCOA4 pathway.Cell communication and signaling : CCS · 2024Article
- A detailed review of pharmacology of MFN1 (mitofusion-1)-mediated mitochondrial dynamics: Implications for cellular health and diseases.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Enhanced Induction of Apoptosis and Cell Cycle Arrest in MCF-7 Breast Cancer and HT-29 Colon Cancer Cell Lines via Low-Dose Biosynthesis of Selenium Nanoparticles Utilizing Lactobacillus casei.Biological trace element research · 2024Article
- Lentinan progress in inflammatory diseases and tumor diseases.European journal of medical research · 2024Review
- Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations.International journal of nanomedicine · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 2 institutions in 1 country.
Hui-Juan LiuState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Yuan QinState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Zi-Han ZhaoState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Yang ZhangDepartment of Anesthesiology, Tianjin Fourth Central Hospital, Tianjin, China.
Jia-Huan YangState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Deng-Hui ZhaiState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Fang CuiState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Ce LuoState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Man-Xi LuState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Piao-Piao LiuState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Heng-Wei XuState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Kun LiState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Bo SunTianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin, China.
Shuang ChenTianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin, China.
Hong-Gang ZhouState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Cheng YangState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Tao SunState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Nankai University · CNTianjin International Joint Academy of Biomedicine · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsApoptosisCaveolaeCell Line, TumorEndocytosisFemaleGTP PhosphohydrolasesHumansLentinanMembrane Potential, MitochondrialMiceMice, Inbred BALB CMitochondriaMitochondrial Membrane Transport ProteinsNanoparticlesAntineoplastic AgentsGTP PhosphohydrolasesLentinanMfn1 protein, humanMitochondrial Membrane Transport ProteinsReactive Oxygen SpeciesSeleniumTLR4 protein, humanTNF Receptor-Associated Factor 3Toll-Like Receptor 4TRAF3 protein, humanlentinanmalignant ascitesmitochondria targeting pathwayovarian cancerselenium nanoparticles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.